Palvella Therapeutics (PVLA) Price & Analysis

Compare

695 Followers

PVLA Stock Chart & Stats

$91.91

-$0.34(-2.31%)

At close: Jan 08 4:00 PM EST

$91.91

-$0.34(-2.31%)

Day’s Range― - ―

52-Week Range$11.17 - $106.71

Previous CloseN/A

Volume11.83K

Average Volume (3M)202.82K

Market Cap

$1.18B

Enterprise Value$646.07M

Total Cash (Recent Filing)$63.57M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta0.06

Next Earnings

Apr 06, 2026

EPS Estimate

-0.91

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.03

Shares Outstanding11,836,490

10 Day Avg. Volume265,123

30 Day Avg. Volume202,822

Financial Highlights & Ratios

PEG Ratio0.01

Price to Book (P/B)0.43

Price to Sales (P/S)0.00

P/FCF Ratio-2.46

Enterprise Value/Market Cap0.55

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-33.81

Forecast

1Y Price Target

$173.20

Price Target Upside88.45% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering15

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Efficacy Of TreatmentThe initial Phase 2 data for QTORIN rapamycin's 2nd indication, cutaneous venous malformation, surpassed expectations with a 73% response rate, indicating an efficient and less expensive pivotal study design.

Financial OutlookThe robust data significantly de-risks the potentially conservative ~$1.6 billion peak sales estimate, leading to an increased price target.

Pipeline ExpansionQTORIN rapamycin will become the first-line therapy for cVM patients if approved, representing a market opportunity of over $500 million.

Bears Say

Market ReactionThe stock was down due to a 'sell the news' market reaction rather than a fundamental issue with the CVM data.

Valuation ConcernsValuation may be the biggest point of pushback on PVLA at this point, despite the $1B+ US peak sales potential and upside from additional indications not currently in the stock.

Palvella Therapeutics News

Palvella Therapeutics price target raised to $133 from $97 at TD Cowen

TD Cowen analyst Ritu Baral raised the firm’s price target on Palvella Therapeutics (PVLA) to $133 from $97...

5d ago

PVLA

Palvella Therapeutics granted FDA Fast Track Designation to QTORIN

Palvella Therapeutics (PVLA) announced that the FDA has granted Fast Track Designation to QTORIN rapamycin for the treatment...

5d ago

PVLA

Palvella Therapeutics price target raised to $204 from $148 at Canaccord

Canaccord analyst Whitney Ijem raised the firm’s price target on Palvella Therapeutics (PVLA) to $204 from $148 and...

5d ago

PVLA

Palvella Therapeutics price target raised to $174 from $110 at Chardan

Chardan raised the firm’s price target on Palvella Therapeutics (PVLA) to $174 from $110 and keeps a Buy...

5d ago

PVLA

Palvella Therapeutics price target raised to $190 from $105 at Truist

Truist raised the firm’s price target on Palvella Therapeutics (PVLA) to $190 from $105 and keeps a Buy...

5d ago

PVLA

Palvella Therapeutics price target raised to $200 from $190 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Palvella Therapeutics (PVLA) to $200 from $190 and keeps a...

5d ago

PVLA

Palvella price target raised to $210 from $200 at Cantor Fitzgerald

Cantor Fitzgerald raised the firm’s price target on Palvella Therapeutics (PVLA) to $210 from $200 and keeps an...

5d ago

PVLA

Palvella Therapeutics price target raised to $200 from $120 at Oppenheimer

Oppenheimer raised the firm’s price target on Palvella Therapeutics (PVLA) to $200 from $120 and keeps an Outperform...

5d ago

PVLA

Palvella Therapeutics price target raised to $212 from $122 at Lucid Capital

Lucid Capital analyst Dev Prasad raised the firm’s price target on Palvella Therapeutics (PVLA) to $212 from $122...

5d ago

PVLA

Palvella Therapeutics announces topline results from Phase 2 TOIVA trial

Palvella Therapeutics (PVLA) announced topline results from the Company’s Phase 2 TOIVA study of QTORIN 3.9% rapamycin anhydrous...

6d ago

PVLA

Buy Rating Affirmed for Palvella Therapeutics Following Promising Phase 2 TOIVA Trial Results

Sam Slutsky, an analyst from LifeSci Capital, maintained the Buy rating on Palvella Therapeutics. The associated price target...

5d ago

PVLA

Promising Clinical Data and Market Potential Drive Buy Rating for Palvella Therapeutics’ QTORIN Rapamycin

Andrew Fein, an analyst from H.C. Wainwright, maintained the Buy rating on Palvella Therapeutics. The associated price target...

5d ago

PVLA

Palvella Therapeutics Reports Positive Phase 2 Study Results

The latest update is out from Palvella Therapeutics ( ($PVLA) ). On December 15, 2025, Palvella Therapeutics announced...

6d ago

PVLA

Positive Buy Rating for Palvella Therapeutics Driven by Promising Developments in DSAP Treatment

In a report released today, Whitney Ijem from Canaccord Genuity maintained a Buy rating on Palvella Therapeutics, with...

16d ago

PVLA

PVLA FAQ

What was Palvella Therapeutics’s price range in the past 12 months?

Palvella Therapeutics lowest stock price was $11.17 and its highest was $106.71 in the past 12 months.

What is Palvella Therapeutics’s market cap?

Palvella Therapeutics’s market cap is $1.18B.

When is Palvella Therapeutics’s upcoming earnings report date?

Palvella Therapeutics’s upcoming earnings report date is Apr 06, 2026 which is in 106 days.

How were Palvella Therapeutics’s earnings last quarter?

Palvella Therapeutics released its earnings results on Nov 11, 2025. The company reported -$1.03 earnings per share for the quarter, missing the consensus estimate of -$0.838 by -$0.192.

Is Palvella Therapeutics overvalued?

According to Wall Street analysts Palvella Therapeutics’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Palvella Therapeutics pay dividends?

Palvella Therapeutics does not currently pay dividends.

What is Palvella Therapeutics’s EPS estimate?

Palvella Therapeutics’s EPS estimate is -0.91.

How many shares outstanding does Palvella Therapeutics have?

Palvella Therapeutics has 11,836,490 shares outstanding.

What happened to Palvella Therapeutics’s price movement after its last earnings report?

Palvella Therapeutics reported an EPS of -$1.03 in its last earnings report, missing expectations of -$0.838. Following the earnings report the stock price went down -3.039%.

Which hedge fund is a major shareholder of Palvella Therapeutics?

Currently, no hedge funds are holding shares in PVLA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Palvella Therapeutics Stock Smart Score

Outperform

Fundamentals

Return on Equity

―

Trailing 12-Months

Asset Growth

226.17%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Palvella Therapeutics

Palvella Therapeutics (PVLA) is a biopharmaceutical company focused on developing and commercializing novel therapies for serious, rare, and genetic dermatological conditions. The company's core product pipeline includes treatments designed to address unmet medical needs in these specialized sectors, leveraging innovative drug delivery systems to enhance patient outcomes.

Palvella Therapeutics (PVLA) Earnings & Revenues

Historic Earnings Reports

PVLA Company Deck

PVLA Earnings Call

Q3 2025

0:00 / 0:00

PVLA Stock 12 Month Forecast

Average Price Target

$173.20

▲(88.45% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"11":"$11","112":"$112","213":"$213","61.5":"$61.5","162.5":"$162.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":212,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$212.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":173.2,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$173.20</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$70.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[11,61.5,112,162.5,213],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.53,103.56615384615385,112.60230769230769,121.63846153846154,130.67461538461538,139.71076923076924,148.74692307692308,157.78307692307692,166.81923076923078,175.85538461538462,184.89153846153846,193.92769230769233,202.96384615384616,{"y":212,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.53,100.58153846153846,106.63307692307693,112.68461538461538,118.73615384615384,124.78769230769231,130.83923076923077,136.89076923076922,142.94230769230768,148.99384615384616,155.0453846153846,161.09692307692308,167.14846153846153,{"y":173.2,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,94.53,92.64307692307692,90.75615384615385,88.86923076923077,86.9823076923077,85.09538461538462,83.20846153846153,81.32153846153847,79.43461538461538,77.5476923076923,75.66076923076923,73.77384615384615,71.88692307692308,{"y":70,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.43,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.59,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":24.09,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.14,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.67,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":36.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":52.71,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.23,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.84,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 34,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.53,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >